FDA has approved Steglatro (ertugliflozin) oral tablets for the treatment of adults with type 2 diabetes. The approval was granted to Merck and Pfizer Inc.
Indications: Steglatro is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dosage and administration: Recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Increase dose to 15 mg once daily in those tolerating Steglatro and needing additional glycemic control. Assess renal function before initiating Steglatro and periodically thereafter.
Adverse reactions: The most common adverse reactions associated with Steglatro (incidence ≤5%) were female genital mycotic infections.
FDA approves SGLT2 inhibitor Steglatro (ertugliflozin) for adults with type 2 diabetes. [news release]. Merck, Pfizer: December 22, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed December 24, 2017.
This Week's Must Reads
Acellular Pertussis Vaccine Is Safe & Effective, JAMA Pediatr; 2018 Nov; Wood, Nolan, et al
Influenza and Pertussis Vaccination in Pregnancy, Vaccine; ePub 2018 Nov 3; Wilcox, Bottrell, et al
Influenza Vaccine Efficacy in High-Risk Patients, Vaccine; ePub 2018 Nov 9; Shang, Chung, et al
Childhood Vaccination Coverage Rates Compared, J Paediatr Child Health; ePub 2018 Nov 13; Baumann, et al
Measles Immunity After Vaccination in Children with HIV, Clin Infect Dis; ePub 2018 Nov 12; Mutsaerts, et al
Must Reads in Diabetes
Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al
BMI & Risk of Postpregnancy T2D in Women with HDP , Diabetes Care; ePub 2018 Nov 19; Timpka, et al
Diabetes Outcomes in Patients by PCPs, NPs, or PAs, Ann Intern Med; ePub 2018 Nov 20; Jackson, et al
Diabetes-Related Lower Extremity Amputations, Diabetes Care; ePub 2018 Nov 8; Geiss, et al
Peer Support Impact in Adults with T2D & Depression, Diabetes Care; ePub 2018 Oct 29; Cherrington, et al